Target intelligence / Profile preview

Ultrasound contrast agent (microbubble) (UCA)

Target
UCA
Molecular classification
Other, Imaging agent (microbubble suspension), Exogenous gas-body contrast medium
01

Overview

“Ultrasound imaging contrast enhancement” does not denote a single therapeutic target or receptor; it refers to exogenous ultrasound contrast agents—stabilized gas microbubbles administered primarily intravenously to increase echogenicity and enable contrast-enhanced ultrasound (CEUS). Clinically approved UCAs are suspensions of gas bodies (e.g., perfluorocarbon, sulfur hexafluoride, nitrogen) encapsulated by shells (lipid, albumin, or polymer). When insonated, microbubbles resonate and exhibit pronounced nonlinear oscillations that generate strong harmonic backscatter, improving blood pool visualization and enabling real-time perfusion assessment. High–mechanical index pulses can intentionally disrupt bubbles to quantify replenishment kinetics. Second-generation agents (e.g., Lumason/SonoVue, Definity/Luminity, Optison, Sonazoid) differ by gas core and shell, which affect stability, circulation time, and, for Sonazoid, Kupffer-cell uptake enabling postvascular liver phase imaging. Approved indications include left ventricular opacification/endocardial border delineation, focal liver lesion characterization, pediatric vesicoureteral reflux assessment, and fallopian tube patency; additional vascular and organ applications exist outside the US and off-label. Research directions include targeted microbubbles for molecular imaging and drug/gene delivery, and emerging protein-based gas vesicles as genetically encodable acoustic reporters. Safety profiles are favorable in routine diagnostic use, though cavitation-mediated bioeffects have been described in preclinical settings and specific cardiac arrhythmias have been rarely reported with certain protocols.

Other names
microbubble contrast agentcontrast-enhanced ultrasound agentCEUS contrast agentgas-body contrast agentsulfur hexafluoride lipid-type A microspheres (example: Lumason/SonoVue)perflutren lipid microspheres (Definity/Luminity)perflutren protein-type A microspheres (Optison)perfluorobutane microbubbles (Sonazoid)
02

Mechanism of action

Acoustic cavitation/nonlinear oscillation of intravascular microbubbles enhances backscatter; High mechanical index pulses can disrupt microbubbles for destruction–replenishment perfusion imaging; Targeted microbubbles bind vascular biomarkers to localize signal (research/adjunct)

03

Biological functions

Intravascular echo enhancementNonlinear ultrasound backscatter generationPerfusion visualization (wash-in/wash-out)Destructibility for replenishment kineticsPotential targeted adhesion/molecular imaging when ligand-decorated
04

Disease associations

Other (diagnostic imaging across cardiovascular and abdominal indications)Cardiovascular disease (left ventricular opacification, endocardial border delineation)Liver disease (characterization of focal liver lesions; Kupffer-phase imaging with Sonazoid)Pediatric urology (vesicoureteral reflux)Infertility workup (tubal patency, HyCoSy)Additional off-label/ex-US uses in breast, portal venous, carotid/peripheral arterial imaging
05

Safety considerations

Potential nonthermal bioeffects related to cavitation (e.g., microvascular leakage, capillary hemorrhage in animal studies)Rare premature ventricular contractions reported with continuous/triggered contrast echocardiographyDisruption of blood–brain barrier reported with therapeutic transcranial ultrasound plus contrastBenign imaging artifacts (e.g., prolonged heterogeneous liver enhancement; “northern lights” microbubble burst band with high MI scanning)

Beyond the preview

Go deeper on Ultrasound contrast agent (microbubble) (UCA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ultrasound contrast agent (microbubble) (UCA).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call